Inhibikase Therapeutics (NYSE:IKT – Get Free Report) and Windtree Therapeutics (NASDAQ:WINT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.
Earnings & Valuation
This table compares Inhibikase Therapeutics and Windtree Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibikase Therapeutics | $260,000.00 | 869.67 | -$19.03 million | ($2.67) | -1.22 |
| Windtree Therapeutics | N/A | N/A | -$20.29 million | ($16.47) | -0.01 |
Inhibikase Therapeutics has higher revenue and earnings than Windtree Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Inhibikase Therapeutics | N/A | -350.63% | -201.82% |
| Windtree Therapeutics | N/A | -362.76% | -79.65% |
Institutional and Insider Ownership
3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 4.6% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 0.3% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Inhibikase Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Inhibikase Therapeutics and Windtree Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibikase Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
| Windtree Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
Inhibikase Therapeutics presently has a consensus price target of $6.50, indicating a potential upside of 99.39%. Windtree Therapeutics has a consensus price target of $350.00, indicating a potential upside of 364,483.33%. Given Windtree Therapeutics’ higher possible upside, analysts clearly believe Windtree Therapeutics is more favorable than Inhibikase Therapeutics.
Summary
Inhibikase Therapeutics beats Windtree Therapeutics on 8 of the 11 factors compared between the two stocks.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
About Windtree Therapeutics
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
